Oxford Immunotec Global PLC (OXFD) Shares Sold by Stonepine Capital Management LLC

Stonepine Capital Management LLC decreased its holdings in Oxford Immunotec Global PLC (NASDAQ:OXFD) by 1.6% in the fourth quarter, HoldingsChannel.com reports. The fund owned 222,321 shares of the company’s stock after selling 3,556 shares during the period. Oxford Immunotec Global comprises about 2.5% of Stonepine Capital Management LLC’s portfolio, making the stock its 15th largest holding. Stonepine Capital Management LLC’s holdings in Oxford Immunotec Global were worth $2,841,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Engineers Gate Manager LP purchased a new stake in Oxford Immunotec Global in the third quarter worth $188,000. Trexquant Investment LP purchased a new position in Oxford Immunotec Global during the third quarter valued at $279,000. Rhumbline Advisers lifted its position in Oxford Immunotec Global by 50.7% during the fourth quarter. Rhumbline Advisers now owns 32,758 shares of the company’s stock valued at $419,000 after buying an additional 11,022 shares during the period. Campbell & CO Investment Adviser LLC purchased a new position in Oxford Immunotec Global during the third quarter valued at $445,000. Finally, Hound Partners LLC purchased a new position in Oxford Immunotec Global during the third quarter valued at $524,000. 91.12% of the stock is owned by institutional investors.

Oxford Immunotec Global stock traded up $0.50 on Monday, hitting $16.26. 1,352 shares of the stock traded hands, compared to its average volume of 124,209. The firm has a market capitalization of $415.45 million, a P/E ratio of -11.88 and a beta of 0.33. Oxford Immunotec Global PLC has a 1 year low of $11.66 and a 1 year high of $19.19.

Several brokerages have commented on OXFD. Piper Jaffray Companies began coverage on Oxford Immunotec Global in a research report on Friday. They set an “overweight” rating for the company. ValuEngine raised Oxford Immunotec Global from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 15th. BidaskClub raised Oxford Immunotec Global from a “sell” rating to a “hold” rating in a research report on Thursday, February 7th. Finally, Zacks Investment Research lowered Oxford Immunotec Global from a “buy” rating to a “hold” rating in a research report on Tuesday, January 15th. Two analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. Oxford Immunotec Global currently has a consensus rating of “Buy” and an average target price of $17.50.

In other news, SVP Elizabeth M. Keiley sold 4,100 shares of Oxford Immunotec Global stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $17.00, for a total value of $69,700.00. Following the completion of the transaction, the senior vice president now owns 26,928 shares of the company’s stock, valued at approximately $457,776. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Peter Wrighton-Smith sold 10,000 shares of Oxford Immunotec Global stock in a transaction dated Thursday, January 10th. The stock was sold at an average price of $14.91, for a total value of $149,100.00. Following the completion of the transaction, the chief executive officer now directly owns 423,469 shares of the company’s stock, valued at approximately $6,313,922.79. The disclosure for this sale can be found here. In the last ninety days, insiders sold 27,100 shares of company stock valued at $431,450. 6.61% of the stock is owned by insiders.

COPYRIGHT VIOLATION WARNING: This report was originally published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this report can be viewed at https://www.chaffeybreeze.com/2019/03/11/oxford-immunotec-global-plc-oxfd-shares-sold-by-stonepine-capital-management-llc.html.

Oxford Immunotec Global Company Profile

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for underserved immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology.

Further Reading: Hedge Funds

Want to see what other hedge funds are holding OXFD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oxford Immunotec Global PLC (NASDAQ:OXFD).

Institutional Ownership by Quarter for Oxford Immunotec Global (NASDAQ:OXFD)

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.